BioSpace News Archive

OSE Immunotherapeutics SA announces that its Chief Scientific Officer Nicolas Poirier will present the latest preclinical progress on the bispecific antibody platform BiCKI® and on the first BiCKI® product, BiCKI®-IL-7, a bifunctional anti-PD-1/interleukin-7 fusion protein, at three upcoming international antibody and immunology conferences.

SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral Nerve Stimulation (PNS) System.

Rosalind Franklin University of Medicine and Science researcher William Frost, PhD, director of the Stanson Toshok Center for Brain Function and Repair within the university’s Brain Science Institute, has been awarded a $1.95 million grant from the National Institutes of Health to study how the brain develops and sustains focus when responding to novel stimuli.

Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease and senior investigator at Gladstone Institutes, has been elected to the National Academy of Medicine.

NeuroPace, Inc., (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors.

T2 Biosystems, Inc. today announced the appointment of Laura Adams to its Board of Directors, effective immediately.

Krystal Biotech Inc. today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy candidate for the treatment of cystic fibrosis, in a poster at the North American Cystic Fibrosis Conference (NACFC) taking place virtually November 2 – 5, 2021.

Zynerba Pharmaceuticals , Inc. today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced an expansion of the clinical development program for the Company’s lead asset, ATH434, in patients with Multiple System Atrophy, a rare and rapidly progressing Parkinsonian disorder.

Context Therapeutics Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $25.0 million, before deducting underwriting discounts, commissions and offering expenses.